Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58 Recent studies advanced science of molecular...
-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation - NASHVILLE, Tenn., June 22, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics...
Peer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to industry-leading competitor GraftAssure’s industry-leading reference change value (time-point...
American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA alone GraftAssure™ assay doubles reliability...
Multiple events and presentations will highlight potential benefits of in-house transplanted-organ-rejection testing, and of GraftAssure technology specifically Major transplantation conference in Boston...
Insight Molecular Diagnostics: Q1 Earnings Snapshot
Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement Northeast kidney transplant center (among the top 10 in the U.S.) is first to...
NASHVILLE, Tenn., May 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report first quarter 2026 financial results after the market...
Positive real-world head-to-head data on GraftAssure TM assay to be presented at the 39 th European Immunogenetics and Histocompatibility Conference (EFI2026), April 21–24, 2026 in Edinburgh, Scotland...
Insight Molecular Diagnostics: Q4 Earnings Snapshot